FGF19型
脂肪组织
FGF21型
肥胖
临床试验
激素
2型糖尿病
医学
脂肪性肝炎
生物信息学
生物
糖尿病
成纤维细胞生长因子
脂肪肝
内分泌学
内科学
疾病
受体
作者
M. Carvalho,Gabriel Machado Chavez Passos Jorge,Luiza Wolf Zanardo,Leticia Miho Hamada,Larissa dos Santos Izabel,Sérgio Santoro,Juliana Magdalon
出处
期刊:American Journal of Physiology-endocrinology and Metabolism
[American Physiological Society]
日期:2024-07-17
标识
DOI:10.1152/ajpendo.00156.2024
摘要
Fibroblast Growth Factor 19 (FGF19) is a hormone synthesized in enterocytes in response to bile acids. The present review explores the pivotal role of FGF19 in metabolism, addressing the urgent global health concern of obesity and its associated pathologies, notably type 2 diabetes. The intriguing inverse correlation between FGF19 and body mass or visceral adiposity, as well as its rapid increase following bariatric surgery, emphasizes its potential as a therapeutic target. This article meticulously examines the impact of FGF19 on metabolism by gathering evidence primarily derived from studies conducted in animal models or cell lines, employing both FGF19 treatment and genetic modifications. Overall, these studies demonstrate that FGF19 has antidiabetic and anti-obesogenic effects. A thorough examination across metabolic tissues, including the liver, adipose tissue, skeletal muscle, and the central nervous system, is conducted, unraveling the intricate interplay of FGF19 across diverse organs. Moreover, we provide a comprehensive overview of clinical trials involving a FGF19 analog called aldafermin, emphasizing promising results in diseases such as non-alcoholic steatohepatitis and diabetes. Therefore, we aim to foster a deeper understanding of FGF19 role and encourage further exploration of its clinical applications, thereby advancing the field and offering innovative approaches to address the escalating global health challenge of obesity and related metabolic conditions.
科研通智能强力驱动
Strongly Powered by AbleSci AI